Page last updated: 2024-08-25

zoledronic acid and Osteolysis

zoledronic acid has been researched along with Osteolysis in 86 studies

Research

Studies (86)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	33 (38.37)	29.6817
2010's	38 (44.19)	24.3611
2020's	15 (17.44)	2.80

Authors

Authors	Studies
Bi, F; Meng, J; Shi, M; Wang, C; Wang, Y; Wu, H; Xu, H; Yan, S; Yang, G; Yao, M; Zhou, C; Zhu, H	1
Billhymer, A; Lundberg, AP; Selting, KA; Tran Hoang, C	1
Lewinski, A; Ludwisiak, M; Mikulak, M; Wojciechowska-Durczynska, K; Zygmunt, A	1
Abe, K; Harata, S; Hongo, M; Igarashi, S; Kasama, F; Kasukawa, Y; Kudo, D; Miyakoshi, N; Nagasawa, H; Nozaka, K; Saito, H; Shoji, R; Tsuchie, H	1
Hong, PY; Huang, MH; Zeng, HQ; Zhang, XB; Zhao, YL	1
Cheng, Y; Ji, Q; Liu, B; Liu, D; Liu, M; Yang, Q; Yang, Z; Zhang, B; Zhou, S	1
Karpiłowska, A; Podgórska, J; Popow, M; Radziszewski, M; Ziółkowska, A	1
Cao, W; Cao, X; Fan, C; Fu, Y; He, W; Hu, X; Kong, X; Li, C; Li, Q; Ling, D; Pang, Y; Qin, A; Sun, X; Wu, Z; Yang, C	1
Kajima, M; Makita, C; Manabe, Y; Matsuo, M; Matsuyama, K; Tanaka, H	1
Ntanasis-Stathopoulos, I; Terpos, E	1
Chen, L; Geng, H; Liu, L; Mei, C	1
Fujita, R; Hamano, H; Hiratsuka, S; Iwasaki, N; Kobayashi, H; Sato, D; Shimizu, T; Takahata, M	1
Ding, Z; Feng, H; Feng, W; Li, J; Li, X; Tang, N; Wang, J; Wu, X; Zhang, P; Zhang, X; Zhao, Q	1
Shang, GQ; Wang, P; Wang, YZ; Xiang, S; Xu, H; Zhang, HN	1
Hakim, SG; Pries, R; Simon, R; Steller, D; Von Bialy, R	1
Chen, H; Wu, FQ; Wu, LG	1
Allegra, A; Allegra, AG; Avenoso, A; Campo, S; D'Ascola, A; Innao, V; Mania, M; Musolino, C; Oteri, G	1
Li, M; Lu, Y; Mao, C; Wan, P; Wang, W; Yang, K; Zhang, Y; Zhu, Y	1
Alexander, S; De-Juan-Pardo, EM; Dondossola, E; Filippini, S; Friedl, P; Hoffman, RM; Holzapfel, BM; Hutmacher, DW; Logothetis, CJ; Navone, N; Starbuck, MW	1
Dimopoulos, MA; Gavriatopoulou, M; Kanellias, N; Terpos, E	1
Chantry, AD; Down, JM; Evans, H; Green, AC; Lath, D; Lawson, MA; Paton-Hough, J; Snowden, JA; Tazzyman, S	1
Bolzoni, M; Ferretti, M; Giuliani, N; Palumbo, C; Toscani, D	1
Cai, X; Hong, J; Hu, B; Lin, T; Shi, Z; Wang, Y; Wu, H; Yan, S; Yang, Y; Ying, Z; Zhao, X	1
Evdokiou, A; Fung, KP; Ko, CH; Lau, CB; Lee, JK; Lee, MY; Leung, PC; Li, G; Luo, KW; Shum, WT; Siu, WS; Yue, GG	1
Bakhous, A; Waheed, S; Zhu, H	1
Han, K; Hu, H; Shen, Z; Sun, Y; Tang, L; Wang, Y; Wu, C; Yao, Y; Zhang, J	1
Bokhari, SW; Jones, FM	1
Ando, T; Cates, JM; Cole, HA; Haro, H; Ohba, T; Schoenecker, JG; Schwartz, HS; Slosky, DA	1
Chikazu, D; Hamada, H; Koizumi, T; Matsuo, A; Satomi, T	1
Ashcroft, AJ; Bell, SE; Boyd, KD; Byrne, J; Child, JA; Cook, G; Davies, FE; Drayson, MT; Feyler, S; Gregory, WM; Jackson, GH; Morgan, GJ; Navarro Coy, N; Osborne, WL; Owen, RG; Roddie, H; Ross, FM; Rudin, C; Szubert, AJ; Wu, P	1
Beck, JT; Bilic, S; Isaacs, R; Iyer, SP; Kelly, KR; Munshi, NC; Sen, S; Shah, J; Stewart, AK	1
Evdokiou, A; Fung, KP; Gao, S; Ko, CH; Lau, CB; Lee, JK; Leung, PC; Li, G; Luo, KW; Yue, GG	1
Fung, KP; Gao, S; Ko, CH; Lau, CB; Lee, JK; Leung, PC; Li, G; Luo, KW; Yue, GG	1
Body, JJ; Casimiro, S; Costa, L	1
Anderson, KC; Argonza-Aviles, E; Badros, A; Ericson, SG; Hadala, JT; Montgomery, CW; Munshi, N; Orlowski, R; Raje, N; Vescio, R; Warsi, G	1
Wu, FQ; Wu, LG; Ye, J	1
Fan, QM; Han, XG; Liu, XQ; Qiao, H; Qin, A; Tang, TT; Wang, TY; Wang, YG; Yu, ZF	1
Cardoso, CL; Cavenago, BC; Curi, MM; Curra, C; Ferreira, O; Matsumoto, MA; Santiago, JF; Santos, PL	1
Atkins, G; DeNichilo, MO; Evdokiou, A; Findlay, D; Hay, S; Ingman, W; Liapis, V; Panagopoulos, V; Ponomarev, V; Zannettino, A; Zinonos, I; Zysk, A	1
Guise, TA; Harhash, AA; John, SK; Kozlow, WM; Marks, AR; Mohammad, KS; Murthy, S; Niewolna, M; Regan, JN; She, Y; Waning, DL; Wright, LE	1
Guo, XE; Liu, Z; Marturano-Kruik, A; Robinson, ST; Villasante, A; Vunjak-Novakovic, G	1
Buijs, JT; Löwik, CW; Papapoulos, SE; Que, I; van der Pluijm, G	1
Evdokiou, A; Findlay, DM; Hay, S; Labrinidis, A; Liapis, V; Ponomarev, V	1
Fenner, M; Hinkmann, FM; Lell, MM; Neukam, FW; Nkenke, E; Stockmann, P; Vairaktaris, E	1
Goto, H; Hanibuchi, M; Ikuta, K; Kakiuchi, S; Nishioka, Y; Ogino, H; Otsuka, S; Sone, S; Takahashi, T; Yamada, T; Yano, S	1
Baslé, MF; Blouin, S; Chappard, D; Libouban, H; Nyangoga, H	1
Berenson, J; Coleman, RE; Cook, RJ; Lipton, A; Terpos, E	1
Allen, MJ; Arrington, SA; Fisher, ER; Mann, KA; Willick, GE	1
Lanigan, LG; Martin, CK; Rosol, TJ; Thudi, NK; Toribio, RE; Werbeck, JL; Wolfe, TD	1
Coleman, R; Cook, R; Hirsh, V; Lipton, A; Major, P	1
Berenson, J; Dimopoulos, MA; Terpos, E	1
Endo, K; Hanaoka, N; Nishisho, T; Takahashi, M; Yasui, N	1
Anderson, KC; Ghobrial, IM; Laubach, JP; Mahindra, A; Mitsiades, CS; Munshi, N; Raje, N; Richardson, PG; Rosenblatt, J; Schlossman, RL	1
Henk, HJ; Kaura, S; Perez, JR; Teitelbaum, A	1
Body, JJ; Brown, J; Coleman, R; Cook, R; Lipton, A; Smith, M	1
Dedes, PG; Gialeli, Ch; Kanakis, I; Karamanos, NK; Kletsas, D; Theocharis, AD; Tsegenidis, T; Tzanakakis, GN	1
Anderson, K; Berenson, JR; Biermann, JS; Hillner, BE; Kyle, RA; Lipton, A; Yee, GC	1
Gleason, D; Gordon, D; Kowalski, MO; Lipton, A; Reitsma, D; Rosen, L; Saad, F; Seaman, J; Small, E; Smith, M	1
Ashcroft, AJ; Davies, FE; Morgan, GJ	1
Denoyelle, C; Hong, L; Soria, C; Soria, J; Vannier, JP	1
Chole, RA; Ebmeyer, J; Faddis, BT; Hildmann, H; Jung, JY; Sudhoff, H	1
Cameron, D	1
Body, JJ	1
Chen, BL; Coleman, RE; Dugan, W; Eisenberg, PD; Gordon, DH; Kaminski, M; Major, P; Provencher, L; Rosen, LS; Seaman, J; Simeone, J	1
Greenberg, MS	1
Bukowski, RM; Colombo-Berra, A; Lipton, A; Rosen, L; Urbanowitz, G; Zheng, M	1
Barden, B; Henschke, F; Hilken, G; Löer, F; Pingsmann, A; Sprecher, C; von Knoch, F; von Knoch, M; Wedemeyer, C	1
Henschke, F; Hilken, G; Löer, F; Pingsmann, A; Saxler, G; Sprecher, C; von Knoch, F; von Knoch, M; Wedemeyer, C	1
Brown, LG; Corey, E; Keller, ET; Quinn, JE; Vessella, RL; Zhang, J	1
Bereiter, H; Heckelei, A; Henschke, F; Hilken, G; Löer, F; Saxler, G; Sprecher, C; von Knoch, F; von Knoch, M; Wedemeyer, C	1
Green, JR	1
Iguchi, H	1
Clézardin, P; Daubiné, F; Gasser, J; Green, J; Le Gall, C	1
Baldini, E; Berto, P; Cortesi, E; Dauria, G; Roila, F; Schivazappa, C	1
Amaddeo, P; Barbaglio, A; Faldi, F; Fontana, S; Ghilardi, R; Pericotti, S	1
Berenson, JR; Coleman, RE; Cook, RJ; Lipton, A; Major, P; Smith, MR; Terpos, E	1
Bäuerle, T; Berger, MR; Peterschmitt, J	1
Bellomi, M; Bruschini, R; Cossu Rocca, M; Goldhirsch, A; Nole, F; Preda, L; Sanna, G; Verri, E	1
Coleman, RE; Cook, RJ; Lipton, A; Major, P; Smith, MR	1
Allen, MJ; Arrington, SA; Damron, TA; Mann, KA	1
Ichikawa, T; Imamoto, T; Kamiya, N; Kawamura, K; Suzuki, H	1
Awad, HA; Bechtold, CD; Bukata, SV; Hock, C; Ito, H; Nakamura, T; O'Keefe, RJ; Proulx, ST; Schwarz, EM; Tsutsumi, R	1
Andrada, E; Cánovas, V; Carrato, A; Guillén-Ponce, C; Guirado-Risueño, M; Martín Hidalgo, A; Molina, MA; Molina, MJ; Molina-Garrido, MJ; Mora, A; Pastor, E	1
Fernandez, SA; Martin, CK; Nadella, MV; Pinzone, JJ; Rosol, TJ; Thudi, NK; Werbeck, JL	1
Ali, SM; Costa, L; Esteva, FJ; Harvey, H; Hortobagyi, G; Knight, R; Lipton, A; Seaman, J	1
Clézardin, P; Delmas, P; Pécheur, I; Peyruchaud, O; Serre, CM; Winding, B	1

Reviews

17 review(s) available for zoledronic acid and Osteolysis

Article	Year
Difficult Therapeutic Decisions in Gorham-Stout Disease-Case Report and Review of the Literature. International journal of environmental research and public health, 2022, 09-16, Volume: 19, Issue:18 Topics: Adult; Female; Humans; Osteolysis; Osteolysis, Essential; Sirolimus; Zoledronic Acid	2022
Controversies in the use of new bone-modifying therapies in multiple myeloma. British journal of haematology, 2021, Volume: 193, Issue:6 Topics: Bone Density Conservation Agents; COVID-19; Denosumab; Diphosphonates; Humans; Hypercalcemia; Multiple Myeloma; Osteolysis; Receptor Activator of Nuclear Factor-kappa B; Renal Insufficiency; Zoledronic Acid	2021
Management of multiple myeloma bone disease: impact of treatment on renal function. Expert review of hematology, 2018, Volume: 11, Issue:11 Topics: Bone Density Conservation Agents; Bone Diseases; Disease Management; Humans; Kidney; Kidney Diseases; Kidney Function Tests; Multiple Myeloma; Osteolysis; Practice Guidelines as Topic; Zoledronic Acid	2018
Role of Osteocytes in Myeloma Bone Disease: Anti-sclerostin Antibody as New Therapeutic Strategy. Frontiers in immunology, 2018, Volume: 9 Topics: Adaptor Proteins, Signal Transducing; Animals; Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Bone Diseases; Bone Morphogenetic Proteins; Bortezomib; Genetic Markers; Humans; Mice; Multiple Myeloma; Osteocytes; Osteogenesis; Osteolysis; Zoledronic Acid	2018
Targeting bone metastases in prostate cancer: improving clinical outcome. Nature reviews. Urology, 2015, Volume: 12, Issue:6 Topics: Antineoplastic Agents; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Drug Therapy, Combination; Humans; Imidazoles; Male; Osteoblasts; Osteolysis; Pain; Prognosis; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radioisotopes; Radiopharmaceuticals; Radium; Treatment Outcome; Zoledronic Acid	2015
Zoledronic acid use in cancer patients: more than just supportive care? Cancer, 2011, Jan-01, Volume: 117, Issue:1 Topics: Biomarkers; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Diphosphonates; Disease-Free Survival; Female; Humans; Imidazoles; Neoplasms; Osteolysis; Zoledronic Acid	2011
Established role of bisphosphonate therapy for prevention of skeletal complications from myeloma bone disease. Critical reviews in oncology/hematology, 2011, Volume: 77 Suppl 1 Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Clodronic Acid; Diphosphonates; Female; Humans; Imidazoles; Mice; Multiple Myeloma; Osteolysis; Pamidronate; Risk Factors; Spinal Cord Compression; Zoledronic Acid	2011
The Medical Research Council Myeloma IX trial: the impact on treatment paradigms. European journal of haematology, 2012, Volume: 88, Issue:1 Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Clinical Trials as Topic; Clodronic Acid; Diphosphonates; Disease-Free Survival; Female; Humans; Imidazoles; Infusions, Intravenous; Male; Multiple Myeloma; Osteolysis; Practice Guidelines as Topic; Zoledronic Acid	2012
The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate. Cancer investigation, 2002, Volume: 20 Suppl 2 Topics: Adenocarcinoma; Biomarkers; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Diphosphonates; Double-Blind Method; Female; Humans; Imidazoles; Infusions, Intravenous; Male; Middle Aged; Multiple Myeloma; Osteoblasts; Osteoclasts; Osteolysis; Osteoporosis; Pain; Pamidronate; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Safety; Zoledronic Acid	2002
Aetiology of bone disease and the role of bisphosphonates in multiple myeloma. The Lancet. Oncology, 2003, Volume: 4, Issue:5 Topics: Antineoplastic Agents; Bone and Bones; Bone Density; Bone Neoplasms; Chemokines; Clinical Trials as Topic; Clodronic Acid; Cytokines; Diphosphonates; Humans; Hypercalcemia; Imidazoles; Multiple Myeloma; Osteolysis; Patient Selection; Treatment Outcome; Zoledronic Acid	2003
Proven efficacy of zoledronic acid in the treatment of bone metastases in patients with breast cancer and other malignancies. Breast (Edinburgh, Scotland), 2003, Volume: 12 Suppl 2 Topics: Bone Neoplasms; Breast Neoplasms; Clinical Trials, Phase III as Topic; Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Imidazoles; Infusions, Intravenous; Male; Osteolysis; Prognosis; Prostatic Neoplasms; Survival Analysis; Treatment Outcome; United Kingdom; Zoledronic Acid	2003
Rationale for the use of bisphosphonates in osteoblastic and osteolytic bone lesions. Breast (Edinburgh, Scotland), 2003, Volume: 12 Suppl 2 Topics: Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clinical Trials, Phase III as Topic; Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Imidazoles; Infusions, Intravenous; Osteoblasts; Osteolysis; Prognosis; Risk Assessment; Survival Analysis; Treatment Outcome; Zoledronic Acid	2003
Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid. Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Sep-15, Volume: 10, Issue:18 Pt 2 Topics: Bone Diseases; Bone Neoplasms; Bone Resorption; Carcinoma, Renal Cell; Diphosphonates; Humans; Imidazoles; Kidney Neoplasms; Neoplasm Metastasis; Osteolysis; Zoledronic Acid	2004
Skeletal complications of prostate cancer: pathophysiology and therapeutic potential of bisphosphonates. Acta oncologica (Stockholm, Sweden), 2005, Volume: 44, Issue:3 Topics: Androgen Antagonists; Animals; Antineoplastic Agents; Bone Density; Bone Diseases; Bone Neoplasms; Diphosphonates; Disease Models, Animal; Humans; Imidazoles; Male; Osteolysis; Prostatic Neoplasms; Tumor Burden; Zoledronic Acid	2005
[Molecular mechanism and potential targets for bone metastasis]. Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:1 Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Male; Mice; Mice, Nude; Neoplastic Cells, Circulating; Osteolysis; Parathyroid Hormone-Related Protein; Prostatic Neoplasms; RANK Ligand; Zoledronic Acid	2007
Clinical utility of biochemical markers of bone metabolism for improving the management of patients with advanced multiple myeloma. Clinical lymphoma & myeloma, 2007, Volume: 7, Issue:5 Topics: Biomarkers; Bone and Bones; Bone Neoplasms; Diphosphonates; Disease Progression; Humans; Imidazoles; Multiple Myeloma; Osteolysis; Predictive Value of Tests; Risk Factors; Survival Rate; Zoledronic Acid	2007
[Bony lesion with prostate cancer]. Clinical calcium, 2008, Volume: 18, Issue:4 Topics: Antibodies, Monoclonal; Azepines; Bone Neoplasms; Cathepsin K; Cathepsins; Diphosphonates; Enzyme Inhibitors; Humans; Imidazoles; Male; Matrix Metalloproteinases; Osteoclasts; Osteolysis; Osteoporosis; Parathyroid Hormone-Related Protein; Prostatic Neoplasms; RANK Ligand; Sulfones; Zoledronic Acid	2008

Trials

9 trial(s) available for zoledronic acid and Osteolysis

Article	Year
Impact of Zoledronic Acid and Denosumab Treatment on Growth Factor Concentration in Platelet Rich Fibrin of Patients With Osteolytic Bone Metastases. Anticancer research, 2021, Volume: 41, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Denosumab; Female; Humans; Intercellular Signaling Peptides and Proteins; Leukocyte Count; Male; Middle Aged; Osteolysis; Platelet Count; Platelet-Rich Fibrin; Prostatic Neoplasms; Young Adult; Zoledronic Acid	2021
Osteonecrosis of the jaw and renal safety in patients with newly diagnosed multiple myeloma: Medical Research Council Myeloma IX Study results. British journal of haematology, 2014, Volume: 166, Issue:1 Topics: Acute Kidney Injury; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Clodronic Acid; Diphosphonates; Drug Administration Schedule; England; Female; Follow-Up Studies; Humans; Imidazoles; Incidence; Male; Middle Aged; Multiple Myeloma; Osteolysis; Zoledronic Acid	2014
A Phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events. British journal of haematology, 2014, Volume: 167, Issue:3 Topics: Aged; Anabolic Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Drug Therapy, Combination; Female; Fractures, Spontaneous; Humans; Hypertension; Imidazoles; Intercellular Signaling Peptides and Proteins; Male; Maximum Tolerated Dose; Middle Aged; Molecular Targeted Therapy; Multiple Myeloma; Neoplasm Proteins; Osteolysis; Recurrence; Spinal Cord Compression; Zoledronic Acid	2014
Bone Marker-Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Multiple Myeloma: Results of the Z-MARK Study. Clinical cancer research : an official journal of the American Association for Cancer Research, 2016, Mar-15, Volume: 22, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Bone Density Conservation Agents; Bone Diseases; Collagen Type I; Diphosphonates; Female; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Osteolysis; Peptides; Zoledronic Acid	2016
Panoramic radiograph, computed tomography or magnetic resonance imaging. Which imaging technique should be preferred in bisphosphonate-associated osteonecrosis of the jaw? A prospective clinical study. Clinical oral investigations, 2010, Volume: 14, Issue:3 Topics: Aged; Bone Density Conservation Agents; Bone Marrow; Contrast Media; Diphosphonates; Female; Follow-Up Studies; Gadolinium; Humans; Imidazoles; Jaw Diseases; Magnetic Resonance Imaging; Male; Mandibular Diseases; Maxillary Diseases; Organometallic Compounds; Osteolysis; Osteonecrosis; Pamidronate; Radiography, Panoramic; Tomography, X-Ray Computed; Zoledronic Acid	2010
Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer, 2004, Jan-01, Volume: 100, Issue:1 Topics: Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Carcinoma; Diphosphonates; Dose-Response Relationship, Drug; Double-Blind Method; Female; Fractures, Bone; Humans; Imidazoles; Infusions, Intravenous; Middle Aged; Osteolysis; Pamidronate; Risk Factors; Spinal Cord Compression; Zoledronic Acid	2004
Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid. Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Sep-15, Volume: 10, Issue:18 Pt 2 Topics: Bone Diseases; Bone Neoplasms; Bone Resorption; Carcinoma, Renal Cell; Diphosphonates; Humans; Imidazoles; Kidney Neoplasms; Neoplasm Metastasis; Osteolysis; Zoledronic Acid	2004
Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity. The oncologist, 2007, Volume: 12, Issue:9 Topics: Biomarkers; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Collagen Type I; Creatinine; Diphosphonates; Female; Follow-Up Studies; Fractures, Bone; Humans; Imidazoles; Injections, Intravenous; Male; Multiple Myeloma; Osteoclasts; Osteolysis; Pamidronate; Peptides; Retrospective Studies; Risk Assessment; Survival Rate; Treatment Outcome; Zoledronic Acid	2007
Safety and efficacy of bisphosphonates beyond 24 months in cancer patients. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Jul-15, Volume: 19, Issue:14 Topics: Bone Neoplasms; Breast Neoplasms; Diphosphonates; Drug Administration Schedule; Female; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Osteolysis; Pamidronate; Time Factors; Zoledronic Acid	2001

Other Studies

61 other study(ies) available for zoledronic acid and Osteolysis

Article	Year
Additive Effect of Parathyroid Hormone and Zoledronate Acid on Prevention Particle Wears-Induced Implant Loosening by Promoting Periprosthetic Bone Architecture and Strength in an Ovariectomized Rat Model. Frontiers in endocrinology, 2022, Volume: 13 Topics: Animals; Bone Density Conservation Agents; Humans; Osteolysis; Osteoporosis; Parathyroid Hormone; Rats; Zoledronic Acid	2022
Combining radiation therapy with zoledronate for the treatment of osteo-invasive feline oral squamous cell carcinoma. Veterinary and comparative oncology, 2022, Volume: 20, Issue:4 Topics: Animals; Bone Density Conservation Agents; Carcinoma, Squamous Cell; Cat Diseases; Cats; Diphosphonates; Head and Neck Neoplasms; Mouth Neoplasms; Osteolysis; Quality of Life; Squamous Cell Carcinoma of Head and Neck; Zoledronic Acid	2022
Intravascular Administration of Acridine Orange and Zoledronate in a Bone Metastasis Model of Breast Cancer. Anticancer research, 2022, Volume: 42, Issue:11 Topics: Acridine Orange; Animals; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; DNA Nucleotidylexotransferase; Female; Imidazoles; Mice; Osteolysis; X-Ray Microtomography; Zoledronic Acid	2022
Gorham-Stout syndrome: A chylothorax disease with bony destruction: A case report. Medicine, 2022, Dec-16, Volume: 101, Issue:50 Topics: Aged; Chylothorax; Humans; Male; Osteolysis; Osteolysis, Essential; Tomography, X-Ray Computed; Vena Cava, Superior; Zoledronic Acid	2022
Calcium phosphate hybrid micelles inhibit orthotopic bone metastasis from triple negative breast cancer by simultaneously killing cancer cells and reprogramming the microenvironment of bone resorption and immunosuppression. Acta biomaterialia, 2023, Volume: 166 Topics: Bone Marrow Diseases; Bone Neoplasms; Calcium Phosphates; Cell Line, Tumor; Docetaxel; Humans; Immunosuppression Therapy; Micelles; Osteolysis; Triple Negative Breast Neoplasms; Tumor Microenvironment; Zoledronic Acid	2023
Life-threatening hypophosphataemia secondary to zoledronic acid implementation in a middle-age patient who presented with advanced osteolysis in the course of multiple myeloma. Endokrynologia Polska, 2020, Volume: 71, Issue:1 Topics: Bone Density Conservation Agents; Humans; Hypophosphatemia; Male; Middle Aged; Multiple Myeloma; Osteolysis; Zoledronic Acid	2020
Metal-Organic Framework Nanoparticles for Ameliorating Breast Cancer-Associated Osteolysis. Nano letters, 2020, 02-12, Volume: 20, Issue:2 Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Diphosphonates; Female; Humans; Metal-Organic Frameworks; Mice; Nanoparticles; Oligodeoxyribonucleotides; Osteoclasts; Osteolysis; Tumor-Associated Macrophages; Zoledronic Acid	2020
Radiation therapy combined with bone-modifying agents ameliorates local control of osteolytic bone metastases in breast cancer. Journal of radiation research, 2020, May-22, Volume: 61, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Breast Neoplasms; Combined Modality Therapy; Denosumab; Female; Humans; Middle Aged; Neoplasm Metastasis; Osteolysis; Pamidronate; Prognosis; Radiotherapy, Conformal; Retrospective Studies; Spine; Zoledronic Acid	2020
Zoledronic Acid Enhanced the Antitumor Effect of Cisplatin on Orthotopic Osteosarcoma by ROS-PI3K/AKT Signaling and Attenuated Osteolysis. Oxidative medicine and cellular longevity, 2021, Volume: 2021 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Cell Line, Tumor; Cisplatin; Drug Synergism; Humans; Mice; Mice, Nude; Osteolysis; Osteosarcoma; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; Signal Transduction; Xenograft Model Antitumor Assays; Zoledronic Acid	2021
Differential effects of anti-RANKL monoclonal antibody and zoledronic acid on necrotic bone in a murine model of Staphylococcus aureus-induced osteomyelitis. Journal of orthopaedic research : official publication of the Orthopaedic Research Society, 2022, Volume: 40, Issue:3 Topics: Animals; Antibodies, Monoclonal; Bone Density Conservation Agents; Disease Models, Animal; Ligands; Mice; Osteoclasts; Osteolysis; Osteomyelitis; Osteonecrosis; RANK Ligand; Staphylococcal Infections; Staphylococcus aureus; X-Ray Microtomography; Zoledronic Acid	2022
A Targeted Erythrocyte Membrane-Encapsulated Drug-Delivery System with Anti-osteosarcoma and Anti-osteolytic Effects. ACS applied materials & interfaces, 2021, Jun-23, Volume: 13, Issue:24 Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Calcium; Cell Line, Tumor; Doxorubicin; Drug Carriers; Drug Liberation; Erythrocyte Membrane; Humans; Metal-Organic Frameworks; Mice, Inbred BALB C; Mice, Nude; Osteolysis; Osteosarcoma; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor A; Zoledronic Acid	2021
Zoledronic acid and teriparatide have a complementary therapeutic effect on aseptic loosening in a rabbit model. BMC musculoskeletal disorders, 2021, Jun-24, Volume: 22, Issue:1 Topics: Animals; Male; Osteoclasts; Osteolysis; Prosthesis Failure; Rabbits; Teriparatide; Titanium; Zoledronic Acid	2021
[Micro-CT evaluating inhibitory effect of zoledronic acid on polyethylene particle-induced periprosthetic osteolysis model]. Zhongguo gu shang = China journal of orthopaedics and traumatology, 2017, Dec-25, Volume: 30, Issue:12 Topics: Animals; Bone Density; Bone Density Conservation Agents; Diphosphonates; Imidazoles; Male; Osteolysis; Polyethylene; Random Allocation; Rats; Rats, Sprague-Dawley; X-Ray Microtomography; Zoledronic Acid	2017
Altered microRNA expression profile in the peripheral lymphoid compartment of multiple myeloma patients with bisphosphonate-induced osteonecrosis of the jaw. Annals of hematology, 2018, Volume: 97, Issue:7 Topics: Aged; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Diphosphonates; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Ontology; Humans; Imidazoles; Lymphocytes; Male; MicroRNAs; Middle Aged; Monocytes; Multiple Myeloma; Osteoclasts; Osteolysis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Neoplasm; Zoledronic Acid	2018
Molecular and cellular mechanisms for zoledronic acid-loaded magnesium-strontium alloys to inhibit giant cell tumors of bone. Acta biomaterialia, 2018, 09-01, Volume: 77 Topics: Alloys; Apoptosis; Biocompatible Materials; Bone and Bones; Bone Neoplasms; Calcium Phosphates; Cell Movement; Cytoskeleton; Diphosphonates; Giant Cell Tumor of Bone; Humans; Magnesium; Mitochondria; Neoplasm Metastasis; Neoplasms; NF-kappa B; Osteoclasts; Osteolysis; Oxidative Stress; Recurrence; Risk Factors; Signal Transduction; Strontium; Zoledronic Acid	2018
Intravital microscopy of osteolytic progression and therapy response of cancer lesions in the bone. Science translational medicine, 2018, 08-01, Volume: 10, Issue:452 Topics: Animals; Bone Marrow; Bone Neoplasms; Cathepsin K; Cell Line, Tumor; Diphosphonates; Disease Progression; Female; Humans; Intravital Microscopy; Male; Mice; Mice, Nude; Miniaturization; Osteolysis; Stromal Cells; Tissue Engineering; Tissue Scaffolds; Treatment Outcome; Zoledronic Acid	2018
Preventing and Repairing Myeloma Bone Disease by Combining Conventional Antiresorptive Treatment With a Bone Anabolic Agent in Murine Models. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2019, Volume: 34, Issue:5 Topics: Animals; Antibodies, Monoclonal; Cell Line, Tumor; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Multiple Myeloma; Neoplasms, Experimental; Osteolysis; Transforming Growth Factor beta; Xenograft Model Antitumor Assays; Zoledronic Acid	2019
Effects of sequential treatment with intermittent parathyroid hormone and zoledronic acid on particle-induced implant loosening: Evidence from a rat model. Journal of orthopaedic research : official publication of the Orthopaedic Research Society, 2019, Volume: 37, Issue:7 Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Drug Evaluation, Preclinical; Male; Osteolysis; Parathyroid Hormone; Prosthesis Failure; Random Allocation; Rats, Sprague-Dawley; X-Ray Microtomography; Zoledronic Acid	2019
Anti-tumor and anti-osteolysis effects of the metronomic use of zoledronic acid in primary and metastatic breast cancer mouse models. Cancer letters, 2013, Oct-01, Volume: 339, Issue:1 Topics: Administration, Metronomic; Animals; Antineoplastic Agents; Bone and Bones; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Mammary Neoplasms, Experimental; Mice; Neoplasm Metastasis; Osteolysis; Radiography; Tumor Burden; Zoledronic Acid	2013
Waldeström macroglobulinaemia relapsing with focal bone disease and achieving major response with single-agent zoledronic acid. British journal of haematology, 2013, Volume: 163, Issue:3 Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Resorption; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Diphosphonates; Hematopoietic Stem Cell Transplantation; Humans; Imidazoles; Male; Melphalan; Middle Aged; Multimodal Imaging; Osteolysis; Positron-Emission Tomography; Pyrazines; Recurrence; Remission Induction; Rituximab; Tomography, X-Ray Computed; Waldenstrom Macroglobulinemia; Zoledronic Acid	2013
Percutaneous vertebroplasty combined with zoledronic acid for the treatment of painful osteolytic spinal metastases in patients with breast cancer. Journal of vascular and interventional radiology : JVIR, 2013, Volume: 24, Issue:12 Topics: Adult; Aged; Back Pain; Bone Density Conservation Agents; Breast Neoplasms; Combined Modality Therapy; Diphosphonates; Drug Administration Schedule; Female; Humans; Imidazoles; Infusions, Intravenous; Karnofsky Performance Status; Middle Aged; Osteolysis; Pain Measurement; Quality of Life; Retrospective Studies; Spinal Neoplasms; Surveys and Questionnaires; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Vertebroplasty; Zoledronic Acid	2013
Hyperammonemic encephalopathy in multiple myeloma. Annals of hematology, 2014, Volume: 93, Issue:8 Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Back Pain; Boronic Acids; Bortezomib; Brain; Brain Edema; Coma; Cyclophosphamide; Dexamethasone; Diphosphonates; Fatal Outcome; Humans; Hyperammonemia; Imidazoles; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Myeloma; Osteolysis; Pyrazines; Tomography, X-Ray Computed; Zoledronic Acid	2014
Bisphosphonates inhibit osteosarcoma-mediated osteolysis via attenuation of tumor expression of MCP-1 and RANKL. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2014, Volume: 29, Issue:6 Topics: Animals; Bone Resorption; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Chemokine CCL2; Diphosphonates; Humans; Imidazoles; Mice; Monocytes; Neoplasm Invasiveness; Osteoclasts; Osteogenesis; Osteolysis; Osteoprotegerin; Osteosarcoma; RANK Ligand; Zoledronic Acid	2014
A simple evaluation method for early detection of bisphosphonate-related osteonecrosis of the mandible using computed tomography. Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery, 2014, Volume: 42, Issue:6 Topics: Administration, Intravenous; Administration, Oral; Alendronate; Alveolar Process; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density; Bone Density Conservation Agents; Case-Control Studies; Diphosphonates; Early Diagnosis; Etidronic Acid; Female; Humans; Image Processing, Computer-Assisted; Imidazoles; Male; Mandible; Mandibular Diseases; Middle Aged; Osteolysis; Osteosclerosis; Pamidronate; Risedronic Acid; Risk Factors; Time Factors; Tomography, X-Ray Computed; Zoledronic Acid	2014
The combined use of Camellia sinensis and metronomic zoledronic acid in a breast cancer-induced osteolysis mouse model. Journal of cancer research and clinical oncology, 2015, Volume: 141, Issue:6 Topics: Administration, Metronomic; Animals; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Camellia sinensis; Cell Line, Tumor; Diphosphonates; Drug Therapy, Combination; Female; Imidazoles; Liver Neoplasms; Luminescent Measurements; Lung Neoplasms; Mammary Neoplasms, Experimental; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mice; Mice, Nude; Osteolysis; Plant Extracts; Zoledronic Acid	2015
The combined use of Camellia sinensis and metronomic zoledronate in 4T1 mouse carcinoma against tumor growth and metastasis. Oncology reports, 2015, Volume: 34, Issue:1 Topics: Administration, Metronomic; Animals; Camellia sinensis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Diphosphonates; Drug Therapy, Combination; Female; Gene Expression Regulation, Neoplastic; Imidazoles; Mammary Neoplasms, Experimental; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mice; Neoplasm Metastasis; Osteolysis; Plant Extracts; Zoledronic Acid	2015
[Inhibitory effect of zoledronate sodium on periprosthetic osteolysis induced by polyethylene particles]. Zhongguo gu shang = China journal of orthopaedics and traumatology, 2015, Volume: 28, Issue:10 Topics: Animals; Bone Density; Collagen Type I; Cytokines; Diphosphonates; Imidazoles; Joint Prosthesis; Male; Osteolysis; Peptides; Polyethylene; Rats; Rats, Sprague-Dawley; Zoledronic Acid	2015
Structural simulation of adenosine phosphate via plumbagin and zoledronic acid competitively targets JNK/Erk to synergistically attenuate osteoclastogenesis in a breast cancer model. Cell death & disease, 2016, Feb-11, Volume: 7 Topics: Adenine Nucleotides; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Diphosphonates; Disease Models, Animal; Drug Synergism; Female; Humans; Imidazoles; JNK Mitogen-Activated Protein Kinases; MAP Kinase Signaling System; Mice; Mice, Inbred BALB C; Mice, Nude; Naphthoquinones; Osteoclasts; Osteolysis; Phosphorylation; Random Allocation; Signal Transduction; Zoledronic Acid	2016
Medication-related osteonecrosis of the jaw. Introduction of a new modified experimental model. Acta cirurgica brasileira, 2016, Volume: 31, Issue:5 Topics: Administration, Intravenous; Alveolar Bone Loss; Animals; Bisphosphonate-Associated Osteonecrosis of the Jaw; Diphosphonates; Imidazoles; Incisor; Male; Maxillary Diseases; Models, Animal; Osteitis; Osteolysis; Rats, Wistar; Tooth Extraction; X-Ray Microtomography; Zoledronic Acid	2016
Adoptive transfer of ex vivo expanded Vγ9Vδ2 T cells in combination with zoledronic acid inhibits cancer growth and limits osteolysis in a murine model of osteolytic breast cancer. Cancer letters, 2017, 02-01, Volume: 386 Topics: Animals; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cytotoxicity, Immunologic; Diphosphonates; Female; Humans; Imidazoles; Immunotherapy, Adoptive; Lung Neoplasms; Lymphocyte Activation; Mice, Inbred NOD; Mice, SCID; Osteolysis; Phenotype; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocytes, Cytotoxic; Time Factors; Xenograft Model Antitumor Assays; Zoledronic Acid	2017
Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo. Oncotarget, 2017, Jan-31, Volume: 8, Issue:5 Topics: Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Diphosphonates; Disease Progression; Estradiol; Female; Humans; Imidazoles; Letrozole; Mice, Inbred BALB C; Mice, Nude; Muscle Strength; Muscle Weakness; Muscle, Skeletal; Nitriles; Osteolysis; Ovariectomy; Receptors, Estrogen; Time Factors; Triazoles; Tumor Burden; Tumor Microenvironment; Xenograft Model Antitumor Assays; Zoledronic Acid	2017
Tissue-Engineered Model of Human Osteolytic Bone Tumor. Tissue engineering. Part C, Methods, 2017, Volume: 23, Issue:2 Topics: Bone Density Conservation Agents; Bone Neoplasms; Cell Differentiation; Cells, Cultured; Diphosphonates; Humans; Imidazoles; Mesenchymal Stem Cells; Models, Biological; Osteoblasts; Osteoclasts; Osteolysis; Sarcoma, Ewing; Tissue Engineering; Zoledronic Acid	2017
Inhibition of bone resorption and growth of breast cancer in the bone microenvironment. Bone, 2009, Volume: 44, Issue:2 Topics: Acid Phosphatase; Animals; Bone and Bones; Bone Resorption; Breast Neoplasms; Cell Count; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Female; Humans; Imidazoles; Isoenzymes; Luminescent Measurements; Mice; Mice, Inbred BALB C; Mice, Nude; Osteoclasts; Osteolysis; Osteoprotegerin; Radiography; Tartrate-Resistant Acid Phosphatase; Whole Body Imaging; Zoledronic Acid	2009
Zoledronic acid inhibits both the osteolytic and osteoblastic components of osteosarcoma lesions in a mouse model. Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, May-15, Volume: 15, Issue:10 Topics: Animals; Apoptosis; Bone Density Conservation Agents; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Disease Progression; Dose-Response Relationship, Drug; Female; Green Fluorescent Proteins; Humans; Imidazoles; Luciferases; Luminescent Measurements; Mice; Mice, Inbred BALB C; Mice, Nude; Osteoblasts; Osteolysis; Osteosarcoma; Recombinant Fusion Proteins; Tibia; Tumor Burden; Xenograft Model Antitumor Assays; Zoledronic Acid	2009
A bone metastasis model with osteolytic and osteoblastic properties of human lung cancer ACC-LC-319/bone2 in natural killer cell-depleted severe combined immunodeficient mice. Oncology research, 2009, Volume: 17, Issue:11-12 Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Bone Neoplasms; Cell Line, Tumor; Diphosphonates; Disease Models, Animal; Endothelin-1; Humans; Imidazoles; Killer Cells, Natural; Lung Neoplasms; Male; Mice; Mice, Inbred ICR; Mice, SCID; Osteoblasts; Osteolysis; Vascular Endothelial Growth Factor A; Zoledronic Acid	2009
A single pretreatment by zoledronic acid converts metastases from osteolytic to osteoblastic in the rat. Microscopy research and technique, 2010, Volume: 73, Issue:8 Topics: Animals; Bone Neoplasms; Diphosphonates; Femur; Imidazoles; Male; Osteoblasts; Osteoclasts; Osteolysis; Prostatic Neoplasms; Rats; X-Ray Microtomography; Zoledronic Acid	2010
Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease. Leukemia, 2010, Volume: 24, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Bone Density Conservation Agents; Bone Diseases; Clinical Trials, Phase III as Topic; Diphosphonates; Double-Blind Method; Female; Humans; Imidazoles; Male; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Osteolysis; Pamidronate; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Rate; Treatment Outcome; Zoledronic Acid	2010
Anabolic and antiresorptive drugs improve trabecular microarchitecture and reduce fracture risk following radiation therapy. Calcified tissue international, 2010, Volume: 87, Issue:3 Topics: Anabolic Agents; Animals; Bone and Bones; Bone Density; Bone Density Conservation Agents; Carcinoma; Diphosphonates; Drug Therapy, Combination; Female; Femoral Neoplasms; Imidazoles; Mice; Mice, Nude; Osteolysis; Parathyroid Hormone; Zoledronic Acid	2010
Zoledronic acid reduces bone loss and tumor growth in an orthotopic xenograft model of osteolytic oral squamous cell carcinoma. Cancer research, 2010, Nov-01, Volume: 70, Issue:21 Topics: Acid Phosphatase; Animals; Bone Density Conservation Agents; Bone Resorption; Calcium; Carcinoma, Squamous Cell; Cats; Diphosphonates; Disease Models, Animal; Imidazoles; Isoenzymes; Luciferases; Male; Mice; Mice, Nude; Mouth Neoplasms; Osteoclasts; Osteolysis; Tartrate-Resistant Acid Phosphatase; Transplantation, Heterologous; X-Ray Microtomography; Zoledronic Acid	2010
Locally administered zoledronic Acid therapy for giant cell tumor of bone. Orthopedics, 2011, Jul-07, Volume: 34, Issue:7 Topics: Adult; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Bone Substitutes; Bone Transplantation; Curettage; Diphosphonates; Giant Cell Tumor of Bone; Humans; Hydroxyapatites; Imidazoles; Knee Joint; Male; Necrosis; Osteoclasts; Osteolysis; Prostheses and Implants; Radiography; Range of Motion, Articular; Remission Induction; Tibia; Zoledronic Acid	2011
Persistency with zoledronic acid is associated with clinical benefit in patients with multiple myeloma. American journal of hematology, 2012, Volume: 87, Issue:5 Topics: Administration, Oral; Aged; Bone Density Conservation Agents; Databases, Factual; Diphosphonates; Drug Utilization; Female; Fractures, Spontaneous; Humans; Imidazoles; Incidence; Infusions, Intravenous; International Classification of Diseases; Male; Medication Adherence; Middle Aged; Multiple Myeloma; Osteolysis; Retrospective Studies; Treatment Outcome; United States; Zoledronic Acid	2012
Skeletal-related events and clinical outcomes in patients with bone metastases and normal levels of osteolysis: exploratory analyses. Clinical oncology (Royal College of Radiologists (Great Britain)), 2013, Volume: 25, Issue:4 Topics: Aged; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Collagen Type I; Diphosphonates; Female; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Osteolysis; Peptides; Prognosis; Proportional Hazards Models; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Treatment Outcome; Zoledronic Acid	2013
Preclinical evaluation of zoledronate using an in vitro mimetic cellular model for breast cancer metastatic bone disease. Biochimica et biophysica acta, 2013, Volume: 1830, Issue:6 Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cathepsin K; Cell Line, Tumor; Coculture Techniques; Collagen Type I; Diphosphonates; Drug Screening Assays, Antitumor; Female; Humans; Imidazoles; Integrin beta3; Macrophage Colony-Stimulating Factor; Models, Biological; Neoplasm Metastasis; Osteoclasts; Osteolysis; RANK Ligand; Zoledronic Acid	2013
American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Sep-01, Volume: 20, Issue:17 Topics: Clodronic Acid; Diphosphonates; Drug Monitoring; Humans; Imidazoles; Multiple Myeloma; Osteolysis; Pamidronate; Zoledronic Acid	2002
New insights into the actions of bisphosphonate zoledronic acid in breast cancer cells by dual RhoA-dependent and -independent effects. British journal of cancer, 2003, May-19, Volume: 88, Issue:10 Topics: Bone Resorption; Breast Neoplasms; Cell Movement; Chemokine CXCL12; Chemokines, CXC; Cyclooxygenase 2; Dinoprostone; Diphosphonates; Dose-Response Relationship, Drug; Female; Gene Expression Regulation; Humans; Imidazoles; Isoenzymes; Membrane Proteins; Neoplasm Invasiveness; Neoplasm Metastasis; Osteolysis; Prostaglandin-Endoperoxide Synthases; rhoA GTP-Binding Protein; Tumor Cells, Cultured; Zoledronic Acid	2003
Zoledronic acid inhibits osteoclastogenesis in vitro and in a mouse model of inflammatory osteolysis. The Annals of otology, rhinology, and laryngology, 2003, Volume: 112, Issue:9 Pt 1 Topics: Animals; Bone Marrow Cells; Bone Resorption; Cell Division; Cells, Cultured; Diphosphonates; Dose-Response Relationship, Drug; Imidazoles; Injections, Subcutaneous; Keratins; Male; Mice; Mice, Inbred C57BL; Minerals; Osteitis; Osteoclasts; Osteolysis; Parietal Bone; Periosteum; Prostheses and Implants; Skull; Zoledronic Acid	2003
Intravenous bisphosphonates and osteonecrosis. Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics, 2004, Volume: 98, Issue:3 Topics: Diphosphonates; Humans; Imidazoles; Injections, Intravenous; Interdisciplinary Communication; Jaw Diseases; Osteolysis; Osteonecrosis; Pamidronate; Zoledronic Acid	2004
The decrease of particle-induced osteolysis after a single dose of bisphosphonate. Biomaterials, 2005, Volume: 26, Issue:14 Topics: Animals; Biocompatible Materials; Diphosphonates; Female; Foreign-Body Reaction; Imidazoles; Injections, Subcutaneous; Male; Materials Testing; Mice; Mice, Inbred C57BL; Osteolysis; Particle Size; Polyethylene; Severity of Illness Index; Treatment Outcome; Zoledronic Acid	2005
Stimulation of bone formation by zoledronic acid in particle-induced osteolysis. Biomaterials, 2005, Volume: 26, Issue:17 Topics: Animals; Diphosphonates; Foreign-Body Reaction; Imidazoles; Mice; Mice, Inbred C57BL; Osteogenesis; Osteolysis; Particle Size; Polyethylenes; Prosthesis Failure; Prosthesis-Related Infections; Skull; Treatment Outcome; Zoledronic Acid	2005
Comparison of Fc-osteoprotegerin and zoledronic acid activities suggests that zoledronic acid inhibits prostate cancer in bone by indirect mechanisms. Prostate cancer and prostatic diseases, 2005, Volume: 8, Issue:3 Topics: Animals; Antibodies; Antineoplastic Agents; Apoptosis; Bone Density; Bone Density Conservation Agents; Bone Neoplasms; Cell Proliferation; Densitometry; Diphosphonates; Glycoproteins; Humans; Imidazoles; Immunoglobulin Fc Fragments; In Vitro Techniques; Male; Mice; Mice, SCID; Neoplasm Metastasis; Osteoclasts; Osteolysis; Osteoprotegerin; Prostatic Neoplasms; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Tibia; Time Factors; Zoledronic Acid	2005
[A comparison of the antiresorptive effects of bisphosphonates and statins on polyethylene particle-induced osteolysis]. Biomedizinische Technik. Biomedical engineering, 2005, Volume: 50, Issue:6 Topics: Animals; Bone Resorption; Diphosphonates; Female; Foreign-Body Reaction; Imidazoles; Male; Mice; Mice, Inbred C57BL; Osteolysis; Particle Size; Polyethylenes; Simvastatin; Skull; Treatment Outcome; Zoledronic Acid	2005
Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. Journal of the National Cancer Institute, 2007, Feb-21, Volume: 99, Issue:4 Topics: Absorptiometry, Photon; Animals; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Neoplasms; Chemotherapy, Adjuvant; Clodronic Acid; Diphosphonates; Drug Administration Schedule; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Green Fluorescent Proteins; Imidazoles; Luciferases; Mammary Neoplasms, Experimental; Mice; Osteolysis; Research Design; Zoledronic Acid	2007
[Cost analysis of tumor-induced osteolysis treated with intravenous zoledronic acid and pamidronate: a time-motion study]. Recenti progressi in medicina, 2007, Volume: 98, Issue:1 Topics: Bone Density Conservation Agents; Costs and Cost Analysis; Diphosphonates; Humans; Imidazoles; Infusions, Intravenous; Neoplasms; Osteolysis; Pamidronate; Time and Motion Studies; Zoledronic Acid	2007
Male breast cancer with mandibular metastasis. A case report. Minerva stomatologica, 2007, Volume: 56, Issue:4 Topics: Aged; Androstadienes; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms, Male; Carcinoma, Ductal, Breast; Cortisone; Cyclophosphamide; Diphosphonates; Docetaxel; Fatal Outcome; Fluorouracil; Furosemide; Humans; Imidazoles; Liver Neoplasms; Male; Mandibular Neoplasms; Mastectomy, Modified Radical; Methotrexate; Omeprazole; Osteolysis; Phenobarbital; Taxoids; Toremifene; Vinblastine; Vinorelbine; Zoledronic Acid	2007
Effect of zoledronic acid and an antibody against bone sialoprotein II on MDA-MB-231(GFP) breast cancer cells in vitro and on osteolytic lesions induced in vivo by this cell line in nude rats. Clinical & experimental metastasis, 2007, Volume: 24, Issue:6 Topics: Animals; Antibodies; Breast Neoplasms; Cell Line, Tumor; Diphosphonates; Green Fluorescent Proteins; Humans; Imidazoles; In Vitro Techniques; Male; Osteolysis; Rats; Rats, Nude; Sialoglycoproteins; Zoledronic Acid	2007
The role of surgery in jaw bone necrosis associated with long-term use of bisphosphonates. Acta oncologica (Stockholm, Sweden), 2008, Volume: 47, Issue:3 Topics: Adenocarcinoma; Bone Neoplasms; Bone Plates; Bone Screws; Breast Neoplasms; Cutaneous Fistula; Diphosphonates; Female; Humans; Imidazoles; Male; Mandible; Mandibular Diseases; Middle Aged; Necrosis; Oral Fistula; Osteolysis; Osteomyelitis; Pamidronate; Prostatic Neoplasms; Recurrence; Tomography, X-Ray Computed; Zoledronic Acid	2008
Concurrent administration of zoledronic acid and irradiation leads to improved bone density, biomechanical strength, and microarchitecture in a mouse model of tumor-induced osteolysis. Journal of surgical oncology, 2008, Mar-01, Volume: 97, Issue:3 Topics: Animals; Bone Density; Bone Density Conservation Agents; Carcinoma; Chemotherapy, Adjuvant; Diphosphonates; Disease Models, Animal; Female; Femoral Neoplasms; Imidazoles; Mice; Osteolysis; Tensile Strength; Tumor Burden; Zoledronic Acid	2008
Differential effects of biologic versus bisphosphonate inhibition of wear debris-induced osteolysis assessed by longitudinal micro-CT. Journal of orthopaedic research : official publication of the Orthopaedic Research Society, 2008, Volume: 26, Issue:10 Topics: Alendronate; Animals; Biocompatible Materials; Bone Density Conservation Agents; Diphosphonates; Disease Models, Animal; Image Processing, Computer-Assisted; Imidazoles; Mice; Osteoclasts; Osteolysis; Osteoprotegerin; Polyethylene; Prosthesis Failure; Skull; Surface Properties; Tomography, X-Ray Computed; Zoledronic Acid	2008
Multiple bone lesions resembling a metastatic origin. An unexpected diagnosis. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2008, Volume: 10, Issue:4 Topics: Aged; Anemia; Back Pain; Bone Density Conservation Agents; Bone Neoplasms; Diagnosis, Differential; Diphosphonates; Female; Humans; Hypertension; Imidazoles; Immunologic Factors; Interferon-alpha; Magnetic Resonance Imaging; Mastocytosis, Systemic; Osteolysis; Osteoporosis; Radionuclide Imaging; Zoledronic Acid	2008
Zoledronic acid decreased osteolysis but not bone metastasis in a nude mouse model of canine prostate cancer with mixed bone lesions. The Prostate, 2008, Jul-01, Volume: 68, Issue:10 Topics: Adenocarcinoma; Animals; Bone Density Conservation Agents; Bone Neoplasms; Cell Line, Transformed; Diphosphonates; Disease Models, Animal; Dogs; Imidazoles; Incidence; Luminescent Proteins; Male; Mice; Mice, Nude; Osteoclasts; Osteolysis; Prostatic Neoplasms; Radiography; Zoledronic Acid	2008
Early detection of bone metastases in a murine model using fluorescent human breast cancer cells: application to the use of the bisphosphonate zoledronic acid in the treatment of osteolytic lesions. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2001, Volume: 16, Issue:11 Topics: Animals; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Green Fluorescent Proteins; Humans; Imidazoles; Luminescent Proteins; Mice; Mice, Nude; Microscopy, Fluorescence; Osteolysis; Recombinant Proteins; Tumor Cells, Cultured; Zoledronic Acid	2001